TRENDS IN COMBINATION LIPID LOWERING THERAPY IN THE MEDICARE POPULATION WITH CORONARY HEART DISEASE  by Bittner, Vera et al.
Prevention
A1481
JACC March 17, 2015
Volume 65, Issue 10S
tRenDs in coMbination lipiD loweRing tHeRapy in tHe MeDicaRe population witH 
coRonaRy HeaRt Disease
Poster Contributions
Poster Hall B1
Sunday, March 15, 2015, 3:45 p.m.-4:30 p.m.
Session Title: Biomarkers, Hypertension and Lipid Management
Abstract Category: 21.  Prevention: Clinical
Presentation Number: 1211-118
Authors: Vera Bittner, Luqin Deng, Robert Rosenson, Ben Taylor, Stephen Glasser, Shia Kent, Michael Farkouh, Paul Muntner, University 
of Alabama at Birmingham, Birmingham, AL, USA, Amgen Inc, Thousand Oaks, CA, USA
background:  Statin use in patients with coronary heart disease (CHD) improves prognosis. Combination lipid-lowering therapy (CLLT: 
statin plus non-statin) can improve the lipid profile, but has not been shown to further reduce risk.
Methods:  We used the 5% sample of Medicare beneficiaries with CHD ≥65 years (N=310,091) to determine the prevalence of CLLT and 
trends over time from 2007 through 2011. History of CHD was defined using Medicare claims and a validated algorithm. CLLT use was 
defined by use of statin with ezetimibe, niacin, fibrates, or bile acid sequestrants (BAS) and identified through pharmacy claims.
Results:  Among Medicare beneficiaries with CHD, CLLT decreased from 23.1% in Q1 of 2007 to 11.7% in Q4 of 2011. Most of the decline 
was due to a 64% decrease in ezetimibe use. Niacin use increased by 42% until Q1 of 2011 and declined 14.7% thereafter. Fibrate use 
increased 21.7% until Q1 of 2011 with a subsequent 3.3% decline. BAS use increased 32.8% over time. Temporal relationships to the 
announcement of results of the ENHANCE, AIM HIGH, and ACCORD studies, respectively, are shown (Figure). Use of CLLT was more 
common among patients <70 years, men, patients with diabetes, on low income subsidies, and those under cardiology care.
conclusion:  CLLT has declined substantially among the Medicare population with CHD. Our data suggest that declines in ezetimibe and 
niacin use, but not fibrate use, were temporally associated with the announcement of negative clinical trial results. 
